GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medtronic PLC (NYSE:MDT) » Definitions » ROE %

Medtronic (Medtronic) ROE %

: 10.24% (As of Jan. 2024)
View and export this data going back to 1980. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Medtronic's annualized net income for the quarter that ended in Jan. 2024 was $5,288 Mil. Medtronic's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was $51,626 Mil. Therefore, Medtronic's annualized ROE % for the quarter that ended in Jan. 2024 was 10.24%.

The historical rank and industry rank for Medtronic's ROE % or its related term are showing as below:

MDT' s ROE % Range Over the Past 10 Years
Min: 6.15   Med: 7.62   Max: 16.08
Current: 8.16

During the past 13 years, Medtronic's highest ROE % was 16.08%. The lowest was 6.15%. And the median was 7.62%.

MDT's ROE % is ranked better than
67.73% of 812 companies
in the Medical Devices & Instruments industry
Industry Median: 0.27 vs MDT: 8.16

Medtronic ROE % Historical Data

The historical data trend for Medtronic's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medtronic Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.19 9.50 7.06 9.69 7.22

Medtronic Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.46 9.16 6.16 7.09 10.24

Competitive Comparison

For the Medical Devices subindustry, Medtronic's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medtronic ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's ROE % distribution charts can be found below:

* The bar in red indicates where Medtronic's ROE % falls into.



Medtronic ROE % Calculation

Medtronic's annualized ROE % for the fiscal year that ended in Apr. 2023 is calculated as

ROE %=Net Income (A: Apr. 2023 )/( (Total Stockholders Equity (A: Apr. 2022 )+Total Stockholders Equity (A: Apr. 2023 ))/ count )
=3758/( (52551+51483)/ 2 )
=3758/52017
=7.22 %

Medtronic's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Oct. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=5288/( (51460+51792)/ 2 )
=5288/51626
=10.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.


Medtronic  (NYSE:MDT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=5288/51626
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(5288 / 32356)*(32356 / 90461.5)*(90461.5 / 51626)
=Net Margin %*Asset Turnover*Equity Multiplier
=16.34 %*0.3577*1.7522
=ROA %*Equity Multiplier
=5.84 %*1.7522
=10.24 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=5288/51626
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (5288 / 5888) * (5888 / 6012) * (6012 / 32356) * (32356 / 90461.5) * (90461.5 / 51626)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8981 * 0.9794 * 18.58 % * 0.3577 * 1.7522
=10.24 %

Note: The net income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Medtronic ROE % Related Terms

Thank you for viewing the detailed overview of Medtronic's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medtronic (Medtronic) Business Description

Address
Lower Hatch Street, 20 On Hatch, Dublin, IRL, 2
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Executives
Brett A. Wall officer: EVP & Group Pres Restora Thera 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Gregory L Smith officer: EVP Global Ops & Supply Chain 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Michael Marinaro officer: EVP & President, Surgical OU 710 MEDTRONIC PARKWAY NE, LC300, MINNEAPOLIS MN 55432
Hoedt Rob Ten officer: EVP & President EMEAC 710 MEDTRONIC PKWY, MSLC300, MINNEAPOLIS MN 55432
Gregory P Lewis director C/O HONEYWELL INTERNATIONAL INC., 300 SOUTH TRYON STREET, CHARLOTTE NC 28202
Sean Salmon officer: EVP & Group President Diabetes MEDTRONIC PLC, 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Lidia Fonseca director 358 SOUTH MAIN STREET, BURLINGTON NC 27215
Karen L Parkhill officer: EVP & Chief Financial Officer 1717 MAIN STREET, MC 6402, DALLAS TX 75201
Ivan K Fong officer: EVP GENERAL COUNSEL & SECR 3M CENTER, ST. PAUL MN 55144-1000
Robert John White officer: EVP & President MITG MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300, MINNEAPOLIS MN 55432
Richard H Anderson director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Bradley E Lerman officer: SVP General Counsel & Corp Sec MEDTRONIC, INC., 710 MEDTRONIC PKWY MSLC300, MINNEAPOLIS MN 55432
Geoffrey Martha officer: Sr VP, Strategy & Bus Dev 710 MEDTRONIC PKWAY, MS LC300, MINNEAPOLIS MN 55432
Jennifer M Kirk officer: Chief Accounting Officer 5 GREENWAY PLAZA, SUITE 110, HOUSTON TX 77046
John R Liddicoat officer: EVP & President of Americas MEDTRONIC PLC, 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432

Medtronic (Medtronic) Headlines